Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

CD8+ T Cells Protect During Vein Graft Disease Development.

Simons KH, de Vries MR, Peters HAB, Jukema JW, Quax PHA, Arens R.

Front Cardiovasc Med. 2019 Jun 13;6:77. doi: 10.3389/fcvm.2019.00077. eCollection 2019.

2.

IRF3 and IRF7 mediate neovascularization via inflammatory cytokines.

Simons KH, de Vries MR, de Jong RCM, Peters HAB, Jukema JW, Quax PHA.

J Cell Mol Med. 2019 Jun;23(6):3888-3896. doi: 10.1111/jcmm.14247. Epub 2019 Apr 1.

3.

The Effect of Corticosteroids on Human Choroidal Endothelial Cells: A Model to Study Central Serous Chorioretinopathy.

Brinks J, van Dijk EHC, Habeeb M, Nikolaou A, Tsonaka R, Peters HAB, Sips HCM, van de Merbel AF, de Jong EK, Notenboom RGE, Kielbasa SM, van der Maarel SM, Quax PHA, Meijer OC, Boon CJF.

Invest Ophthalmol Vis Sci. 2018 Nov 1;59(13):5682-5692. doi: 10.1167/iovs.18-25054.

PMID:
30489628
4.

Blockade of vascular endothelial growth factor receptor 2 inhibits intraplaque haemorrhage by normalization of plaque neovessels.

de Vries MR, Parma L, Peters HAB, Schepers A, Hamming JF, Jukema JW, Goumans MJTH, Guo L, Finn AV, Virmani R, Ozaki CK, Quax PHA.

J Intern Med. 2019 Jan;285(1):59-74. doi: 10.1111/joim.12821. Epub 2018 Sep 7.

5.

The protective role of Toll-like receptor 3 and type-I interferons in the pathophysiology of vein graft disease.

Simons KH, de Vries MR, Peters HAB, Hamming JF, Jukema JW, Quax PHA.

J Mol Cell Cardiol. 2018 Aug;121:16-24. doi: 10.1016/j.yjmcc.2018.06.001. Epub 2018 Jun 4.

PMID:
29879406
6.

The role of CD27-CD70-mediated T cell co-stimulation in vasculogenesis, arteriogenesis and angiogenesis.

Simons KH, Aref Z, Peters HAB, Welten SP, Nossent AY, Jukema JW, Hamming JF, Arens R, de Vries MR, Quax PHA.

Int J Cardiol. 2018 Jun 1;260:184-190. doi: 10.1016/j.ijcard.2018.02.015.

7.

Adenosine-to-Inosine Editing of MicroRNA-487b Alters Target Gene Selection After Ischemia and Promotes Neovascularization.

van der Kwast RVCT, van Ingen E, Parma L, Peters HAB, Quax PHA, Nossent AY.

Circ Res. 2018 Feb 2;122(3):444-456. doi: 10.1161/CIRCRESAHA.117.312345. Epub 2017 Dec 28.

PMID:
29284691
8.

The epigenetic factor PCAF regulates vascular inflammation and is essential for intimal hyperplasia development.

de Jong RCM, Ewing MM, de Vries MR, Karper JC, Bastiaansen AJNM, Peters HAB, Baghana F, van den Elsen PJ, Gongora C, Jukema JW, Quax PHA.

PLoS One. 2017 Oct 10;12(10):e0185820. doi: 10.1371/journal.pone.0185820. eCollection 2017.

9.

A protective role of IRF3 and IRF7 signalling downstream TLRs in the development of vein graft disease via type I interferons.

Simons KH, Peters HAB, Jukema JW, de Vries MR, Quax PHA.

J Intern Med. 2017 Dec;282(6):522-536. doi: 10.1111/joim.12679. Epub 2017 Sep 27.

10.

Short hairpin RNA gene silencing of prolyl hydroxylase-2 with a minicircle vector improves neovascularization of hindlimb ischemia.

Lijkwan MA, Hellingman AA, Bos EJ, van der Bogt KE, Huang M, Kooreman NG, de Vries MR, Peters HA, Robbins RC, Hamming JF, Quax PH, Wu JC.

Hum Gene Ther. 2014 Jan;25(1):41-9. doi: 10.1089/hum.2013.110. Epub 2014 Jan 7.

11.

C57BL/6 NK cell gene complex is crucially involved in vascular remodeling.

de Vries MR, Seghers L, van Bergen J, Peters HA, de Jong RC, Hamming JF, Toes RE, van Hinsbergh VW, Quax PH.

J Mol Cell Cardiol. 2013 Nov;64:51-8. doi: 10.1016/j.yjmcc.2013.08.009. Epub 2013 Sep 5.

PMID:
24013026
12.

T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development.

Ewing MM, Karper JC, Abdul S, de Jong RC, Peters HA, de Vries MR, Redeker A, Kuiper J, Toes RE, Arens R, Jukema JW, Quax PH.

Int J Cardiol. 2013 Oct 3;168(3):1965-74. doi: 10.1016/j.ijcard.2012.12.085. Epub 2013 Jan 23.

14.

Herbivore control of annual grassland composition in current and future environments.

Peters HA, Cleland EE, Mooney HA, Field CB.

Ecol Lett. 2006 Jan;9(1):86-94.

PMID:
16958872
15.

Gastropod herbivory in response to elevated CO2 and N addition impacts plant community composition.

Cleland EE, Peters HA, Mooney HA, Field CB.

Ecology. 2006 Mar;87(3):686-94.

PMID:
16602298
16.

Spousal surcharge programs--an overview.

Peters HA.

Benefits Q. 2005;21(1):19-25. Review.

PMID:
15825633
17.

Falling palm fronds structure amazonian rainforest sapling communities.

Peters HA, Pauw A, Silman MR, Terborgh JW.

Proc Biol Sci. 2004 Aug 7;271 Suppl 5:S367-9.

18.

The prognostic value of BCAR1 in patients with primary breast cancer.

Dorssers LC, Grebenchtchikov N, Brinkman A, Look MP, van Broekhoven SP, de Jong D, Peters HA, Portengen H, Meijer-van Gelder ME, Klijn JG, van Tienoven DT, Geurts-Moespot A, Span PN, Foekens JA, Sweep FC.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6194-202.

19.

Development of an ELISA for measurement of BCAR1 protein in human breast cancer tissue.

Grebenchtchikov N, Brinkman A, van Broekhoven SP, de Jong D, Geurts-Moespot A, Span PN, Peters HA, Portengen H, Foekens JA, Sweep CG, Dorssers LC.

Clin Chem. 2004 Aug;50(8):1356-63.

20.

Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.

Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JG, Foekens JA.

Cancer Res. 2004 Jul 1;64(13):4563-8.

21.

Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.

Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brünner N, Foekens JA.

Clin Cancer Res. 2004 Apr 1;10(7):2289-98.

22.

Clinical confirmation of trichothecene mycotoxicosis in patient urine.

Croft WA, Jastromski BM, Croft AL, Peters HA.

J Environ Biol. 2002 Jul;23(3):301-20.

PMID:
12597576
23.

Clinical relevance of biologic factors in male breast cancer.

Meijer-van Gelder ME, Look MP, Bolt-de Vries J, Peters HA, Klijn JG, Foekens JA.

Breast Cancer Res Treat. 2001 Aug;68(3):249-60.

PMID:
11727961
24.

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.

Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, Klijn JG.

Cancer Res. 2001 Jul 15;61(14):5407-14.

25.

Consumption rates and food preferences of slugs in a calcareous grassland under current and future CO2 conditions.

Peters HA, Baur B, Bazzaz F, Körner C.

Oecologia. 2000 Oct;125(1):72-81. doi: 10.1007/PL00008893.

PMID:
28308224
26.

The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group.

Salden M, Splinter TA, Peters HA, Look MP, Timmermans M, van Meerbeeck JP, Foekens JA.

Ann Oncol. 2000 Mar;11(3):327-32.

PMID:
10811500
27.

The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.

Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.

Cancer Res. 2000 Feb 1;60(3):636-43.

28.

Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.

de Witte JH, Sweep CG, Klijn JG, Grebenschikov N, Peters HA, Look MP, van Tienoven TH, Heuvel JJ, Bolt-De Vries J, Benraad TJ, Foekens JA.

Br J Cancer. 1999 Apr;80(1-2):286-94.

29.

Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse.

Meijer-van Gelder ME, Look MP, Bolt-de Vries J, Peters HA, Klijn JG, Foekens JA.

J Clin Oncol. 1999 May;17(5):1449-57.

PMID:
10334530
30.

Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.

de Witte JH, Sweep CG, Klijn JG, Grebenschikov N, Peters HA, Look MP, van Tienoven TH, Heuvel JJ, van Putten WL, Benraad TJ, Foekens JA.

Br J Cancer. 1999 Mar;79(7-8):1190-8.

31.

Uptake and distribution of doxorubicin in hormone-manipulated human breast cancer cells in vitro.

Bontenbal M, Sieuwerts AM, Peters HA, van Putten WL, Foekens JA, Klijn JG.

Breast Cancer Res Treat. 1998 Sep;51(2):139-48.

PMID:
9879776
32.

Acute intermittent porphyria.

Peters HA, Levine R, Cripps D.

Neurology. 1998 Jun;50(6):1932-3. No abstract available.

PMID:
9633780
33.
34.

Prognostic significance of cathepsins B and L in primary human breast cancer.

Foekens JA, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.

J Clin Oncol. 1998 Mar;16(3):1013-21.

PMID:
9508185
36.

Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.

Grøndahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Rønne E, Dano K, Klijn JG, Brünner N, Foekens JA.

Clin Cancer Res. 1995 Oct;1(10):1079-87.

37.

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.

Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG.

J Natl Cancer Inst. 1995 May 17;87(10):751-6.

PMID:
7563153
38.

Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.

Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WL, Look MP, Klijn JG, Kramer MD.

Cancer Res. 1995 Apr 1;55(7):1423-7.

39.

Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.

Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Jänicke F, Klijn JG.

J Clin Oncol. 1994 Aug;12(8):1648-58.

PMID:
8040677
40.

Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro.

Foekens JA, Sieuwerts AM, Stuurman-Smeets EM, Peters HA, Klijn JG.

Br J Cancer. 1993 Feb;67(2):232-6.

41.

Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.

Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, Klijn JG.

Cancer Res. 1992 Nov 1;52(21):6101-5.

42.

Finger tremor after carbon disulfide-based pesticide exposures.

Chapman LJ, Sauter SL, Henning RA, Levine RL, Matthews CG, Peters HA.

Arch Neurol. 1991 Aug;48(8):866-70.

PMID:
1898265
43.

Manipulation of cell cycle kinetics: influence on the cytotoxicity of doxorubicin in human breast cancer cells.

Bontenbal M, Sieuwerts AM, Peters HA, Sonneveld P, Foekens JA, Klijn JG.

J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1097-101.

PMID:
2285583
44.

Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studies.

Klijn JG, Setyono-Han B, Bakker GH, van der Burg ME, Bontenbal M, Peters HA, Sieuwerts AM, Berns PM, Foekens JA.

J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1089-95. Review.

PMID:
1981013
45.

Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells.

Bontenbal M, Sieuwerts AM, Klijn JG, Peters HA, Krijnen HL, Sonneveld P, Foekens JA.

Br J Cancer. 1989 Nov;60(5):688-92.

46.

Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.

Foekens JA, Portengen H, van Putten WL, Peters HA, Krijnen HL, Alexieva-Figusch J, Klijn JG.

Cancer Res. 1989 Nov 1;49(21):5823-8.

47.

Preparatory processes in a case of hemi-parkinsonism.

Stelmach GE, Worringham CJ, Peters HA.

J Neurol. 1989 Mar;236(3):174-6.

PMID:
2709067
48.

Hexachlorobenzene episode in Turkey.

Gocmen A, Peters HA, Cripps DJ, Bryan GT, Morris CR.

Biomed Environ Sci. 1989 Mar;2(1):36-43.

PMID:
2590490
49.

Extrapyramidal and other neurologic manifestations associated with carbon disulfide fumigant exposure.

Peters HA, Levine RL, Matthews CG, Chapman LJ.

Arch Neurol. 1988 May;45(5):537-40.

PMID:
2833878
50.

The effects of post-exercise glucose and alanine ingestion on plasma carnitine and ketosis in humans.

Carlin JI, Olson EB Jr, Peters HA, Reddan WG.

J Physiol. 1987 Sep;390:295-303.

Supplemental Content

Loading ...
Support Center